on is urging the U.S. Supreme Court to take up its appeal of a divided Federal Circuit decision that struck down part of its patented arthritis drug Pennsaid, saying the ruling "casts a pall of uncertainty" over the validity of tens of thousands of patents with similar phrasing. [Continue Reading] WSJ: [